Can urinary exosomes act as treatment response markers in prostate cancer?

被引:227
作者
Mitchell, Paul J. [1 ]
Welton, Joanne [1 ]
Staffurth, John [1 ]
Court, Jacquelyn [2 ]
Mason, Malcolm D. [1 ]
Tabi, Zsuzsanna [1 ]
Clayton, Aled [1 ]
机构
[1] Cardiff Univ, Sch Med, Velindre Canc Ctr, Sect Oncol & Palliat Med, Cardiff CF14 2TL, S Glam, Wales
[2] Velindre Canc Ctr, Velindre NHS Trust, Canc Serv Div, Cardiff CF14 2TL, S Glam, Wales
关键词
TUMOR-DERIVED EXOSOMES; ANTIGEN; BIOMARKER; METHYLATION; PROMOTE; GROWTH; CELLS; GSTP1;
D O I
10.1186/1479-5876-7-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Recently, nanometer sized vesicles ( termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy. Methods: Ten patients ( with locally advanced PCa) provided spot urine specimens at three time points during standard therapy. Patients received 3-6 months neoadjuvant androgen deprivation therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant ADT according to clinical need. Exosomes were purified, and the phenotype compared to exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present in urine were quantified, and expression of prostate markers ( PSA and PSMA) and tumour-associated marker 5T4 was examined. Results: The quantity and quality of exosomes present in urine was highly variable, even though we handled all materials freshly and used methods optimized for obtaining highly pure exosomes. There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa specimens, and not detected in healthy donor specimens. There was a clear treatment-related decrease in exosomal prostate markers in 1 ( of 8) patient. Conclusion: Evaluating urinary-exosomes remains difficult, given the variability of exosomes in urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple markers of malignancy that could provide clinically useful information.
引用
收藏
页数:13
相关论文
共 35 条
[1]   URINARY TISSUE FACTOR LEVELS IN PROSTATIC-CARCINOMA - A POTENTIAL MARKER OF METASTATIC SPREAD [J].
ADAMSON, AS ;
FRANCIS, JL ;
WITHEROW, RO ;
SNELL, ME .
BRITISH JOURNAL OF UROLOGY, 1993, 71 (05) :587-592
[2]   Malignant effusions and immunogenic tumour-derived exosomes [J].
Andre, F ;
Schartz, NEC ;
Movassagh, M ;
Flament, C ;
Pautier, P ;
Morice, P ;
Pomel, C ;
Lhomme, C ;
Escudier, B ;
Le Chevalier, T ;
Tursz, T ;
Amigorena, S ;
Raposo, G ;
Angevin, E ;
Zitvogel, L .
LANCET, 2002, 360 (9329) :295-305
[3]   Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity [J].
Botchkina, GI ;
Kim, RH ;
Botchkina, IL ;
Kirshenbaum, A ;
Frischer, Z ;
Adler, HL .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3243-3249
[4]  
CARSBERG CJ, 1995, J CELL SCI, V108, P2905
[5]   Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy:: A longitudinal study of protein kinetics throughout tumor progression and therapy [J].
Chan, LW ;
Moses, MA ;
Goley, E ;
Sproull, M ;
Muanza, T ;
Coleman, CN ;
Figg, WD ;
Albert, PS ;
Ménard, C ;
Camphausen, K .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :499-506
[6]   Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry [J].
Clayton, A ;
Court, J ;
Navabi, H ;
Adams, M ;
Mason, MD ;
Hobot, JA ;
Newman, GR ;
Jasani, B .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 247 (1-2) :163-174
[7]   Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59 [J].
Clayton, A ;
Harris, CL ;
Court, J ;
Mason, MD ;
Morgan, BP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (02) :522-531
[8]   Human tumor-derived exosomes down-modulate NKG2D expression [J].
Clayton, Aled ;
Mitchell, J. Paul ;
Court, Jacquelyn ;
Linnane, Seamus ;
Mason, Malcolm D. ;
Tabi, Zsuzsanna .
JOURNAL OF IMMUNOLOGY, 2008, 180 (11) :7249-7258
[9]   Human tumor-derived exosomes selectively impair lymphocyte responses to interieukin-2 [J].
Clayton, Aled ;
Mitchell, J. Paul ;
Court, Jacquelyn ;
Mason, Malcolm D. ;
Tabi, Zsuzsanna .
CANCER RESEARCH, 2007, 67 (15) :7458-7466
[10]   Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results [J].
Crocitto, LE ;
Korns, D ;
Kretzner, L ;
Shevchuk, T ;
Blair, SL ;
Wilson, TG ;
Ramin, SA ;
Kawachi, MH ;
Smith, SS .
UROLOGY, 2004, 64 (04) :821-825